InvaGen Pharmaceuticals, Inc.; Proposal To Withdraw Approval of an Abbreviated New Drug Application for Trandolapril Tablets; Opportunity for a Hearing, 57736-57739 [2019-23461]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
57736
Federal Register / Vol. 84, No. 208 / Monday, October 28, 2019 / Notices
PaperworkReductionActof1995/PRAListing.html
1. Email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov.
2. Call the Reports Clearance Office at
(410) 786–1326.
FOR FURTHER INFORMATION CONTACT:
William Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. The term ‘‘collection of
information’’ is defined in 44 U.S.C.
3502(3) and 5 CFR 1320.3(c) and
includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires federal agencies
to publish a 30-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension or
reinstatement of an existing collection
of information, before submitting the
collection to OMB for approval. To
comply with this requirement, CMS is
publishing this notice that summarizes
the following proposed collection(s) of
information for public comment:
1. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Establishment of
Exchanges and Qualified Health Plans;
Use: The Patient Protection and
Affordable Care Act (Pub. L. 111–148)
and the Health Care and Education
Reconciliation Act of 2010 (Pub. L.111–
152) (collectively, the Patient Protection
and Affordable Care Act (PPACA)) were
signed into law in 2010. The PPACA
established competitive private health
insurance markets, called Marketplaces
or Exchanges, which give millions of
Americans and small businesses access
to qualified health plans (QHPs),
including stand-alone dental plans
(SADPs)—private health and dental
insurance plans that are certified as
meeting certain standards.
As directed by the rule Establishment
of Exchanges and Qualified Health
Plans; Exchange Standards for
Employers (77 FR 18310) (Exchange
rule), each Exchange assumed
responsibilities related to the
certification and offering of QHPs.
Under 45 CFR 156.280(e)(5)(ii), each
QHP issuer that offers non-excepted
abortion services must submit to the
State Insurance Commissioner a
VerDate Sep<11>2014
16:58 Oct 25, 2019
Jkt 250001
segregation plan describing how the
QHP issuer establishes and maintains
separate payment accounts for any QHP
covering non-excepted abortion
services, and pursuant to
§ 156.280(e)(5)(iii), each QHP issuer
must annually attest to compliance with
PPACA section 1303 and applicable
regulations. This segregation plan is
used to verify that the QHP issuer’s
financial and other systems fully
conform to the segregation requirements
required by the PPACA. Form Number:
CMS–10400 (OMB control number
0938–1156); Frequency: Annually;
Affected Public: Private Sector (business
or other for-profits, not-for-profit
institutions); Number of Respondents:
210; Number of Responses: 210; Total
Annual Hours: 580. For questions
regarding this collection contact
Michele Oshman at 410–786–4396.
Dated: October 23, 2019.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2019–23506 Filed 10–25–19; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–3708]
InvaGen Pharmaceuticals, Inc.;
Proposal To Withdraw Approval of an
Abbreviated New Drug Application for
Trandolapril Tablets; Opportunity for a
Hearing
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration’s (FDA or Agency)
Center for Drug Evaluation and Research
(CDER) is proposing to withdraw
approval of an abbreviated new drug
application (ANDA) for trandolapril
tablets and is announcing an
opportunity for the holder of the ANDA
to request a hearing on this proposal.
The basis for the proposal is that the
holder of the ANDA has repeatedly
failed to submit the required data to
support a finding of bioequivalence for
this ANDA.
DATES: InvaGen Pharmaceuticals, Inc.
may submit a request for a hearing by
November 27, 2019. Submit all data,
information, and analyses upon which
the request for a hearing relies by
December 27, 2019. Submit electronic or
written comments by December 27,
2019.
SUMMARY:
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
The request for a hearing
may be submitted by InvaGen
Pharmaceuticals, Inc. by either of the
following methods:
ADDRESSES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments to
submit your request for a hearing.
Comments submitted electronically to
https://www.regulations.gov, including
any attachments to the request for a
hearing, will be posted to the docket
unchanged.
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• Because your request for a hearing
will be made public, you are solely
responsible for ensuring that your
request does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. The request
for a hearing must include the Docket
No. FDA–2019–N–3708 for ‘‘InvaGen
Pharmaceuticals, Inc.; Proposal to
Withdraw Approval of an Abbreviated
New Drug Application for Trandolapril
Tablets; Opportunity for a Hearing.’’
The request for a hearing will be placed
in the docket and publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
InvaGen Pharmaceuticals, Inc. may
submit all data and analyses upon
which the request for a hearing relies in
the same manner as the request for a
hearing except as follows:
• Confidential Submissions—To
submit any data and analyses with
confidential information that you do not
wish to be made publicly available,
submit your data and analyses only as
a written/paper submission. You should
submit two copies total of all data and
analyses. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of any decisions on
this matter. The second copy, which
E:\FR\FM\28OCN1.SGM
28OCN1
Federal Register / Vol. 84, No. 208 / Monday, October 28, 2019 / Notices
will have the claimed confidential
information redacted/blacked out, will
be available for public viewing and
posted on https://www.regulations.gov
or available at the Dockets Management
Staff between 9 a.m. and 4 p.m.,
Monday through Friday. Submit both
copies to the Dockets Management Staff.
Any information marked as
‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law.
Comments Submitted by Other
Interested Parties: For all comments
submitted by other interested parties,
submit comments as follows.
khammond on DSKJM1Z7X2PROD with NOTICES
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2019–N–3708 for ‘‘InvaGen
Pharmaceuticals, Inc.; Proposal to
Withdraw Approval of an Abbreviated
VerDate Sep<11>2014
16:58 Oct 25, 2019
Jkt 250001
New Drug Application for Trandolapril
Tablets; Opportunity for a Hearing.’’
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Maryll W. Toufanian, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 75, Rm. 1720,
Silver Spring, MD 20993–0002, 240–
402–7944.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
57737
I. Background
A. Approval of ANDA 078320 for
Trandolapril Tablets
FDA’s Office of Generic Drugs (OGD)
approved ANDA 078320, held by
InvaGen Pharmaceuticals, Inc.
(InvaGen), for a generic version of
trandolapril tablets, 1 milligram (mg), 2
mg, and 4 mg, under the requirements
of section 505(j) of the Federal Food,
Drug, and Cosmetic Act (FD&C Act) (21
U.S.C. 355(j)) and FDA’s implementing
regulations. OGD approved ANDA
078320 on June 12, 2007.
In seeking approval of its ANDA
078320, InvaGen relied on the reference
listed drug (RLD) product, MAVIK
(trandolapril) tablets, 1 mg, 2 mg, and 4
mg, approved under new drug
application (NDA) 020528 (see § 314.94
(21 CFR 314.94)). As an applicant under
section 505(j) of the FD&C Act, InvaGen
was not required to conduct clinical
studies to demonstrate the safety and
effectiveness of its drug product. Rather,
in addition to meeting the other
requirements for ANDA approval
enumerated in section 505(j) of the
FD&C Act and applicable FDA
regulations, InvaGen was required to
demonstrate that its product was
bioequivalent to the RLD, MAVIK (see
section 505(j)(2)(A)(iv) and (j)(4)(F) of
the FD&C Act; § 314.94(a)(7); 21 CFR
314.127(a)(6)(i)). The information that
InvaGen submitted to show that its
ANDA 078320 was bioequivalent to the
RLD included bioequivalence studies,
with the bioanalytical analysis
conducted by Cetero Research at the
Houston, TX site during 2005–2006.
B. Investigations Regarding
Bioequivalence Studies Conducted by
Cetero Research
In May 2010 and December 2010,
FDA conducted comprehensive
inspections of bioequivalence studies
conducted by Cetero Research at the
Houston, TX site. The inspections were
part of FDA’s Bioresearch Monitoring
Program, which includes inspections to
evaluate the conduct of research, to
confirm that data intended for
submission to FDA are reliable as a
basis for FDA approval and regulatory
decisions, and to verify compliance
with the bioavailability and
bioequivalence requirements in section
505 of the FD&C Act and 21 CFR part
320. The findings of these inspections of
bioequivalence studies conducted by
Cetero Research raised significant
concerns about the validity of the
reported results of analytical studies
conducted between April 1, 2005, and
June 15, 2010, in support of drug
applications (see Ref. 1). The
E:\FR\FM\28OCN1.SGM
28OCN1
khammond on DSKJM1Z7X2PROD with NOTICES
57738
Federal Register / Vol. 84, No. 208 / Monday, October 28, 2019 / Notices
inspections and a third-party audit
identified significant instances of
misconduct and violations of Federal
regulations, including document
falsification and sample manipulation.
The pattern of misconduct was serious
enough to raise concerns about the
integrity of the data that Cetero Research
generated during the 5-year time frame
between 2005 and 2010. On July 26,
2011, FDA notified pharmaceutical
companies that bioanalytical studies
conducted at Cetero Research between
April 1, 2005, and June 15, 2010, in
support of marketing applications may
need to be repeated or confirmed (see
Ref. 2).
On August 9, 2011, FDA issued a
letter to InvaGen regarding ANDA
078320 because this drug product
application was supported by
bioequivalence studies with the
bioanalytical analysis conducted by
Cetero Research at the Houston, TX site
between April 1, 2005, and June 15,
2010 (see Ref. 3). As FDA noted in its
August 9, 2011, correspondence,
inspection findings regarding Cetero
Research’s bioequivalence studies raised
significant concerns about the validity
of the reported results of the analytical
studies conducted between April 2005
and June 2010 in support of drug
applications, and as such, steps needed
to be taken to demonstrate the
bioequivalence of InvaGen’s drug
product approved under ANDA 078320.
FDA informed InvaGen that ANDA
078320 needed to be supplemented by
conducting new bioequivalence studies
or re-assaying the samples from the
original bioequivalence study. FDA
recommended to InvaGen that the
results of the requested bioequivalence
studies, or re-assays, be submitted to
ANDA 078320 within 6 months of the
date of the August 9, 2011, letter. As
noted in the August 9, 2011,
correspondence, if the necessary
information was not submitted within
the recommended timeframe, FDA
would consider downgrading the
therapeutic equivalence evaluation of
approved applications in the Agency’s
‘‘Approved Drug Products With
Therapeutic Equivalence Evaluations’’
(Orange Book) from an ‘‘AB’’ to a ‘‘BX’’
rating because of new information
raising a significant question as to
bioequivalence. FDA did not receive a
response from InvaGen to this August 9,
2011, correspondence.
On August 19, 2016, FDA issued
another letter to InvaGen requesting
that, within 30 calendar days, InvaGen
either: (1) Supplement ANDA 078320
with the requested bioequivalence data
or (2) voluntarily seek withdrawal of
ANDA 078320 under § 314.150 (21 CFR
VerDate Sep<11>2014
16:58 Oct 25, 2019
Jkt 250001
314.150(d)) and waive the opportunity
for a hearing under § 314.150(a) (see Ref.
4). As noted in the August 19, 2016,
correspondence, if InvaGen did not
submit new bioequivalence data within
30 calendar days, if the new data did
not support a finding of bioequivalence,
or if InvaGen did not agree to
voluntarily seek withdrawal of ANDA
078320 within 30 calendar days, FDA
would commence downgrading the
therapeutic equivalence evaluation of
approved applications in the Orange
Book from an ‘‘AB’’ to a ‘‘BX’’ rating.
FDA also stated that if the
aforementioned conditions were not
met, FDA would consider all other
appropriate regulatory action, including
commencing steps to withdraw
approval of ANDA 078320 under
section 505(e) of the FD&C Act and
§ 314.150. In response to the August 19,
2016, correspondence, FDA received a
letter from InvaGen dated September 16,
2016, requesting a 9-month extension
and stating that InvaGen was working to
conduct new studies to submit to the
Agency (see Ref. 5).
On April 24, 2017, FDA issued a third
letter to InvaGen notifying them that
FDA was denying InvaGen’s request for
a 9-month extension because InvaGen
had already had a lengthy period to
provide the requested data (see Ref. 6).
In the April 24, 2017, correspondence,
FDA also notified InvaGen that FDA had
changed the therapeutic equivalence
evaluation of ANDA 078320 in the
Orange Book from an ‘‘AB’’ to a ‘‘BX’’
rating. Further, in the April 24, 2017,
correspondence, FDA requested that
InvaGen voluntarily seek withdrawal for
ANDA 078320 under § 314.150(d) and
waive the opportunity for a hearing
under § 314.150(a). FDA requested that
InvaGen provide such a withdrawal
request or a letter stating that InvaGen
would not voluntarily seek withdrawal
of the approval of ANDA 078320 no
later than May 24, 2017. As noted in the
April 24, 2017, correspondence, FDA
advised InvaGen that if InvaGen did not
agree to voluntarily seek withdrawal of
the approval of ANDA 078320 under
§ 314.150(d), FDA would plan to
commence steps to withdraw approval
of this ANDA under 505(e) of the FD&C
Act and § 314.150. FDA did not receive
a response from InvaGen to this April
24, 2017, correspondence.
In the June 2017 Cumulative
Supplement to the 37th Edition of the
Orange Book, ANDA 078320 was moved
to the Discontinued Section of the
Orange Book based on notification by
InvaGen to the Agency that InvaGen was
no longer marketing its drug product
approved under ANDA 078320. Because
drug products that are in the
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Discontinued Section of the Orange
Book do not have therapeutic
equivalence codes and because ANDA
078320 is currently in the Discontinued
Section of the Orange Book, ANDA
078320 is not currently assigned a
therapeutic equivalence code.
II. Conclusions and Proposed Action
An NDA applicant must submit ‘‘full
reports of investigations’’ to show that
the drug for which the applicant is
seeking approval is safe and effective. In
other words, NDAs must meet the safety
and substantial evidence of
effectiveness standard (see section
505(b)(1) and (2), (c), and (d) of the
FD&C Act). An NDA applicant can meet
the standard by conducting its own
clinical studies (stand-alone
application) or relying, in part, on the
Agency’s previous finding of safety and/
or effectiveness or literature (a 505(b)(2)
application). An ANDA applicant does
not submit independent clinical studies
to demonstrate safety and effectiveness.
Rather, an ANDA applicant relies on the
Agency’s previous finding of safety and
effectiveness for its RLD and is required
to meet other requirements, such as
demonstrating bioequivalence to the
RLD to support approval. In the absence
of information showing bioequivalence
between the generic drug at issue and
the RLD, there is no basis for concluding
that the Agency’s finding of safety and
efficacy supporting approval of the RLD
can be used as a basis to support
approval of the generic drug. Section
505(e) of the FD&C Act provides FDA
the authority to withdraw approval of
an ANDA in these circumstances. While
the InvaGen application was approved
on the basis of a bioequivalence study,
new information about the facility that
conducted the bioanalytical analysis for
that study leads CDER to conclude that
the results of that study are not credible.
Therefore, based on all available data
and information, notice is given to
InvaGen Pharmaceuticals, Inc. and to all
other interested persons that the
Director of CDER proposes to issue an
order, under section 505(e) of the FD&C
Act and § 314.150, withdrawing
approval of ANDA 078320 and all
amendments and supplements to it on
the grounds that InvaGen has failed to
submit the required bioequivalence data
necessary to demonstrate the
bioequivalence of its drug product.
III. Hearing Procedures
In accordance with section 505(e) of
the FD&C Act, InvaGen
Pharmaceuticals, Inc. is hereby
provided an opportunity to request a
hearing to show why approval of ANDA
078320 should not be withdrawn and an
E:\FR\FM\28OCN1.SGM
28OCN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 84, No. 208 / Monday, October 28, 2019 / Notices
opportunity to raise, for administrative
determination, all issues relating to the
legal status of the drug product covered
by this application.
An applicant who decides to seek a
hearing must file the following: (1) A
written notice of participation and
request for a hearing (see DATES and
ADDRESSES) and (2) the data,
information, and analyses relied on to
demonstrate that there is a genuine and
substantial issue of fact that requires a
hearing (see DATES and ADDRESSES). Any
other interested person may also submit
comments on this notice. The
procedures and requirements governing
this notice of opportunity for a hearing,
notice of participation and request for a
hearing, the information and analyses to
justify a hearing, other comments, and
a grant or denial of a hearing are
contained in § 314.200 (21 CFR 314.200)
and in 21 CFR part 12.
The failure of an applicant to file a
timely written notice of participation
and request for a hearing, as required by
§ 314.200, constitutes an election by that
applicant not to avail itself of the
opportunity for a hearing concerning
CDER’s proposal to withdraw approval
of the application and constitutes a
waiver of any contentions concerning
the legal status of the drug product. FDA
will then withdraw approval of the
application, and the drug product may
not thereafter be lawfully introduced or
delivered for introduction into interstate
commerce. Any new drug product
introduced or delivered for introduction
into interstate commerce without an
approved application is subject to
regulatory action at any time.
A request for a hearing may not rest
upon mere allegations or denials but
must present specific facts showing that
there is a genuine and substantial issue
of fact that requires a hearing. If a
request for a hearing is not complete or
is not supported, the Commissioner of
Food and Drugs will enter summary
judgment against the person who
requests the hearing, making findings
and conclusions, and denying a hearing.
Paper submissions under this notice
of opportunity for a hearing must be
filed in two copies. Except for data and
information prohibited from public
disclosure under 21 U.S.C. 331(j) or 18
U.S.C. 1905, the submissions may be
seen at the Dockets Management Staff
(see ADDRESSES) between 9 a.m. and 4
p.m., Monday through Friday, and will
be posted to the docket at https://
www.regulations.gov.
This notice is issued under section
505(e) of the FD&C Act and under
authority delegated to the Director of
CDER by the Commissioner of Food and
Drugs.
VerDate Sep<11>2014
16:58 Oct 25, 2019
Jkt 250001
IV. References
The following references are on
display at the Dockets Management Staff
(see ADDRESSES) and are available for
viewing by interested persons between
9 a.m. and 4 p.m., Monday through
Friday; they are also available
electronically at https://
www.regulations.gov. FDA has verified
the website address, as of the date this
document publishes in the Federal
Register, but websites are subject to
change over time.
1. Letter from Leslie Ball, FDA, to Roger
Hayes, Cetero Research, July 26, 2011.
2. FDA, ‘‘Notification to Pharmaceutical
Companies: Acceptance of third-party
data integrity audit for Cetero studies
conducted from March 1, 2008, to
August 31, 2009’’ (https://
wayback.archive-it.org/7993/
20170113203457/http:/www.fda.gov/
Drugs/DrugSafety/ucm265559.htm),
accessed September 10, 2019.
3. Letter from Keith Webber, FDA, to InvaGen
Pharmaceuticals, Inc., August 9, 2011.
4. Letter from Carol A. Holquist, FDA, to
InvaGen Pharmaceuticals, Inc., August
19, 2016.
5. Letter from Ram Mohan Kathuroju,
InvaGen Pharmaceuticals, Inc., to FDA,
September 16, 2016.
6. Letter from Carol A. Holquist, FDA, to
InvaGen Pharmaceuticals, Inc., April 24,
2017.
Dated: October 21, 2019.
Janet Woodcock,
Director, Center for Drug Evaluation and
Research.
[FR Doc. 2019–23461 Filed 10–25–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–3723]
Watson Laboratories, Inc.; Proposal To
Withdraw Approval of an Abbreviated
New Drug Application for Oxycodone
Hydrochloride and Ibuprofen Tablets;
Opportunity for a Hearing
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration’s (FDA or Agency)
Center for Drug Evaluation and Research
(CDER) is proposing to withdraw
approval of an abbreviated new drug
application (ANDA) for oxycodone
hydrochloride and ibuprofen tablets and
is announcing an opportunity for the
holder of the ANDA to request a hearing
on this proposal. The basis for the
proposal is that the holder of the ANDA
SUMMARY:
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
57739
has repeatedly failed to submit the
required data to support a finding of
bioequivalence for this ANDA.
DATES: Watson Laboratories, Inc. may
submit a request for a hearing by
November 27, 2019. Submit all data,
information, and analyses upon which
the request for a hearing relies by
December 27, 2019. Submit electronic or
written comments by December 27,
2019.
The request for a hearing
may be submitted by Watson
Laboratories, Inc. by either of the
following methods:
ADDRESSES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments to
submit your request for a hearing.
Comments submitted electronically to
https://www.regulations.gov, including
any attachments to the request for a
hearing, will be posted to the docket
unchanged.
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• Because your request for a hearing
will be made public, you are solely
responsible for ensuring that your
request does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. The request
for a hearing must include the Docket
No. FDA–2019–N–3723 for ‘‘Watson
Laboratories, Inc.; Proposal to Withdraw
Approval of an Abbreviated New Drug
Application for Oxycodone
Hydrochloride and Ibuprofen Tablets;
Opportunity for a Hearing.’’ The request
for a hearing will be placed in the
docket and publicly viewable at https://
www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4
p.m., Monday through Friday.
Watson Laboratories, Inc., may submit
all data and analyses upon which the
request for a hearing relies in the same
manner as the request for a hearing
except as follows:
• Confidential Submissions—To
submit any data and analyses with
confidential information that you do not
wish to be made publicly available,
E:\FR\FM\28OCN1.SGM
28OCN1
]]>Agencies
[Federal Register Volume 84, Number 208 (Monday, October 28, 2019)]
[Notices]
[Pages 57736-57739]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-23461]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2019-N-3708]
InvaGen Pharmaceuticals, Inc.; Proposal To Withdraw Approval of
an Abbreviated New Drug Application for Trandolapril Tablets;
Opportunity for a Hearing
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration's (FDA or Agency) Center for
Drug Evaluation and Research (CDER) is proposing to withdraw approval
of an abbreviated new drug application (ANDA) for trandolapril tablets
and is announcing an opportunity for the holder of the ANDA to request
a hearing on this proposal. The basis for the proposal is that the
holder of the ANDA has repeatedly failed to submit the required data to
support a finding of bioequivalence for this ANDA.
DATES: InvaGen Pharmaceuticals, Inc. may submit a request for a hearing
by November 27, 2019. Submit all data, information, and analyses upon
which the request for a hearing relies by December 27, 2019. Submit
electronic or written comments by December 27, 2019.
ADDRESSES: The request for a hearing may be submitted by InvaGen
Pharmaceuticals, Inc. by either of the following methods:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments to submit your request
for a hearing. Comments submitted electronically to https://www.regulations.gov, including any attachments to the request for a
hearing, will be posted to the docket unchanged.
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
Because your request for a hearing will be made public,
you are solely responsible for ensuring that your request does not
include any confidential information that you or a third party may not
wish to be posted, such as medical information, your or anyone else's
Social Security number, or confidential business information, such as a
manufacturing process. The request for a hearing must include the
Docket No. FDA-2019-N-3708 for ``InvaGen Pharmaceuticals, Inc.;
Proposal to Withdraw Approval of an Abbreviated New Drug Application
for Trandolapril Tablets; Opportunity for a Hearing.'' The request for
a hearing will be placed in the docket and publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
InvaGen Pharmaceuticals, Inc. may submit all data and analyses upon
which the request for a hearing relies in the same manner as the
request for a hearing except as follows:
Confidential Submissions--To submit any data and analyses
with confidential information that you do not wish to be made publicly
available, submit your data and analyses only as a written/paper
submission. You should submit two copies total of all data and
analyses. One copy will include the information you claim to be
confidential with a heading or cover note that states ``THIS DOCUMENT
CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy,
including the claimed confidential information, in its consideration of
any decisions on this matter. The second copy, which
[[Page 57737]]
will have the claimed confidential information redacted/blacked out,
will be available for public viewing and posted on https://www.regulations.gov or available at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday through Friday. Submit both copies to
the Dockets Management Staff. Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law.
Comments Submitted by Other Interested Parties: For all comments
submitted by other interested parties, submit comments as follows.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2019-N-3708 for ``InvaGen Pharmaceuticals, Inc.; Proposal to
Withdraw Approval of an Abbreviated New Drug Application for
Trandolapril Tablets; Opportunity for a Hearing.'' Received comments,
those filed in a timely manner (see ADDRESSES), will be placed in the
docket and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Maryll W. Toufanian, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 75, Rm. 1720, Silver Spring, MD 20993-0002, 240-
402-7944.
SUPPLEMENTARY INFORMATION:
I. Background
A. Approval of ANDA 078320 for Trandolapril Tablets
FDA's Office of Generic Drugs (OGD) approved ANDA 078320, held by
InvaGen Pharmaceuticals, Inc. (InvaGen), for a generic version of
trandolapril tablets, 1 milligram (mg), 2 mg, and 4 mg, under the
requirements of section 505(j) of the Federal Food, Drug, and Cosmetic
Act (FD&C Act) (21 U.S.C. 355(j)) and FDA's implementing regulations.
OGD approved ANDA 078320 on June 12, 2007.
In seeking approval of its ANDA 078320, InvaGen relied on the
reference listed drug (RLD) product, MAVIK (trandolapril) tablets, 1
mg, 2 mg, and 4 mg, approved under new drug application (NDA) 020528
(see Sec. 314.94 (21 CFR 314.94)). As an applicant under section
505(j) of the FD&C Act, InvaGen was not required to conduct clinical
studies to demonstrate the safety and effectiveness of its drug
product. Rather, in addition to meeting the other requirements for ANDA
approval enumerated in section 505(j) of the FD&C Act and applicable
FDA regulations, InvaGen was required to demonstrate that its product
was bioequivalent to the RLD, MAVIK (see section 505(j)(2)(A)(iv) and
(j)(4)(F) of the FD&C Act; Sec. 314.94(a)(7); 21 CFR
314.127(a)(6)(i)). The information that InvaGen submitted to show that
its ANDA 078320 was bioequivalent to the RLD included bioequivalence
studies, with the bioanalytical analysis conducted by Cetero Research
at the Houston, TX site during 2005-2006.
B. Investigations Regarding Bioequivalence Studies Conducted by Cetero
Research
In May 2010 and December 2010, FDA conducted comprehensive
inspections of bioequivalence studies conducted by Cetero Research at
the Houston, TX site. The inspections were part of FDA's Bioresearch
Monitoring Program, which includes inspections to evaluate the conduct
of research, to confirm that data intended for submission to FDA are
reliable as a basis for FDA approval and regulatory decisions, and to
verify compliance with the bioavailability and bioequivalence
requirements in section 505 of the FD&C Act and 21 CFR part 320. The
findings of these inspections of bioequivalence studies conducted by
Cetero Research raised significant concerns about the validity of the
reported results of analytical studies conducted between April 1, 2005,
and June 15, 2010, in support of drug applications (see Ref. 1). The
[[Page 57738]]
inspections and a third-party audit identified significant instances of
misconduct and violations of Federal regulations, including document
falsification and sample manipulation. The pattern of misconduct was
serious enough to raise concerns about the integrity of the data that
Cetero Research generated during the 5-year time frame between 2005 and
2010. On July 26, 2011, FDA notified pharmaceutical companies that
bioanalytical studies conducted at Cetero Research between April 1,
2005, and June 15, 2010, in support of marketing applications may need
to be repeated or confirmed (see Ref. 2).
On August 9, 2011, FDA issued a letter to InvaGen regarding ANDA
078320 because this drug product application was supported by
bioequivalence studies with the bioanalytical analysis conducted by
Cetero Research at the Houston, TX site between April 1, 2005, and June
15, 2010 (see Ref. 3). As FDA noted in its August 9, 2011,
correspondence, inspection findings regarding Cetero Research's
bioequivalence studies raised significant concerns about the validity
of the reported results of the analytical studies conducted between
April 2005 and June 2010 in support of drug applications, and as such,
steps needed to be taken to demonstrate the bioequivalence of InvaGen's
drug product approved under ANDA 078320. FDA informed InvaGen that ANDA
078320 needed to be supplemented by conducting new bioequivalence
studies or re-assaying the samples from the original bioequivalence
study. FDA recommended to InvaGen that the results of the requested
bioequivalence studies, or re-assays, be submitted to ANDA 078320
within 6 months of the date of the August 9, 2011, letter. As noted in
the August 9, 2011, correspondence, if the necessary information was
not submitted within the recommended timeframe, FDA would consider
downgrading the therapeutic equivalence evaluation of approved
applications in the Agency's ``Approved Drug Products With Therapeutic
Equivalence Evaluations'' (Orange Book) from an ``AB'' to a ``BX''
rating because of new information raising a significant question as to
bioequivalence. FDA did not receive a response from InvaGen to this
August 9, 2011, correspondence.
On August 19, 2016, FDA issued another letter to InvaGen requesting
that, within 30 calendar days, InvaGen either: (1) Supplement ANDA
078320 with the requested bioequivalence data or (2) voluntarily seek
withdrawal of ANDA 078320 under Sec. 314.150 (21 CFR 314.150(d)) and
waive the opportunity for a hearing under Sec. 314.150(a) (see Ref.
4). As noted in the August 19, 2016, correspondence, if InvaGen did not
submit new bioequivalence data within 30 calendar days, if the new data
did not support a finding of bioequivalence, or if InvaGen did not
agree to voluntarily seek withdrawal of ANDA 078320 within 30 calendar
days, FDA would commence downgrading the therapeutic equivalence
evaluation of approved applications in the Orange Book from an ``AB''
to a ``BX'' rating. FDA also stated that if the aforementioned
conditions were not met, FDA would consider all other appropriate
regulatory action, including commencing steps to withdraw approval of
ANDA 078320 under section 505(e) of the FD&C Act and Sec. 314.150. In
response to the August 19, 2016, correspondence, FDA received a letter
from InvaGen dated September 16, 2016, requesting a 9-month extension
and stating that InvaGen was working to conduct new studies to submit
to the Agency (see Ref. 5).
On April 24, 2017, FDA issued a third letter to InvaGen notifying
them that FDA was denying InvaGen's request for a 9-month extension
because InvaGen had already had a lengthy period to provide the
requested data (see Ref. 6). In the April 24, 2017, correspondence, FDA
also notified InvaGen that FDA had changed the therapeutic equivalence
evaluation of ANDA 078320 in the Orange Book from an ``AB'' to a ``BX''
rating. Further, in the April 24, 2017, correspondence, FDA requested
that InvaGen voluntarily seek withdrawal for ANDA 078320 under Sec.
314.150(d) and waive the opportunity for a hearing under Sec.
314.150(a). FDA requested that InvaGen provide such a withdrawal
request or a letter stating that InvaGen would not voluntarily seek
withdrawal of the approval of ANDA 078320 no later than May 24, 2017.
As noted in the April 24, 2017, correspondence, FDA advised InvaGen
that if InvaGen did not agree to voluntarily seek withdrawal of the
approval of ANDA 078320 under Sec. 314.150(d), FDA would plan to
commence steps to withdraw approval of this ANDA under 505(e) of the
FD&C Act and Sec. 314.150. FDA did not receive a response from InvaGen
to this April 24, 2017, correspondence.
In the June 2017 Cumulative Supplement to the 37th Edition of the
Orange Book, ANDA 078320 was moved to the Discontinued Section of the
Orange Book based on notification by InvaGen to the Agency that InvaGen
was no longer marketing its drug product approved under ANDA 078320.
Because drug products that are in the Discontinued Section of the
Orange Book do not have therapeutic equivalence codes and because ANDA
078320 is currently in the Discontinued Section of the Orange Book,
ANDA 078320 is not currently assigned a therapeutic equivalence code.
II. Conclusions and Proposed Action
An NDA applicant must submit ``full reports of investigations'' to
show that the drug for which the applicant is seeking approval is safe
and effective. In other words, NDAs must meet the safety and
substantial evidence of effectiveness standard (see section 505(b)(1)
and (2), (c), and (d) of the FD&C Act). An NDA applicant can meet the
standard by conducting its own clinical studies (stand-alone
application) or relying, in part, on the Agency's previous finding of
safety and/or effectiveness or literature (a 505(b)(2) application). An
ANDA applicant does not submit independent clinical studies to
demonstrate safety and effectiveness. Rather, an ANDA applicant relies
on the Agency's previous finding of safety and effectiveness for its
RLD and is required to meet other requirements, such as demonstrating
bioequivalence to the RLD to support approval. In the absence of
information showing bioequivalence between the generic drug at issue
and the RLD, there is no basis for concluding that the Agency's finding
of safety and efficacy supporting approval of the RLD can be used as a
basis to support approval of the generic drug. Section 505(e) of the
FD&C Act provides FDA the authority to withdraw approval of an ANDA in
these circumstances. While the InvaGen application was approved on the
basis of a bioequivalence study, new information about the facility
that conducted the bioanalytical analysis for that study leads CDER to
conclude that the results of that study are not credible.
Therefore, based on all available data and information, notice is
given to InvaGen Pharmaceuticals, Inc. and to all other interested
persons that the Director of CDER proposes to issue an order, under
section 505(e) of the FD&C Act and Sec. 314.150, withdrawing approval
of ANDA 078320 and all amendments and supplements to it on the grounds
that InvaGen has failed to submit the required bioequivalence data
necessary to demonstrate the bioequivalence of its drug product.
III. Hearing Procedures
In accordance with section 505(e) of the FD&C Act, InvaGen
Pharmaceuticals, Inc. is hereby provided an opportunity to request a
hearing to show why approval of ANDA 078320 should not be withdrawn and
an
[[Page 57739]]
opportunity to raise, for administrative determination, all issues
relating to the legal status of the drug product covered by this
application.
An applicant who decides to seek a hearing must file the following:
(1) A written notice of participation and request for a hearing (see
DATES and ADDRESSES) and (2) the data, information, and analyses relied
on to demonstrate that there is a genuine and substantial issue of fact
that requires a hearing (see DATES and ADDRESSES). Any other interested
person may also submit comments on this notice. The procedures and
requirements governing this notice of opportunity for a hearing, notice
of participation and request for a hearing, the information and
analyses to justify a hearing, other comments, and a grant or denial of
a hearing are contained in Sec. 314.200 (21 CFR 314.200) and in 21 CFR
part 12.
The failure of an applicant to file a timely written notice of
participation and request for a hearing, as required by Sec. 314.200,
constitutes an election by that applicant not to avail itself of the
opportunity for a hearing concerning CDER's proposal to withdraw
approval of the application and constitutes a waiver of any contentions
concerning the legal status of the drug product. FDA will then withdraw
approval of the application, and the drug product may not thereafter be
lawfully introduced or delivered for introduction into interstate
commerce. Any new drug product introduced or delivered for introduction
into interstate commerce without an approved application is subject to
regulatory action at any time.
A request for a hearing may not rest upon mere allegations or
denials but must present specific facts showing that there is a genuine
and substantial issue of fact that requires a hearing. If a request for
a hearing is not complete or is not supported, the Commissioner of Food
and Drugs will enter summary judgment against the person who requests
the hearing, making findings and conclusions, and denying a hearing.
Paper submissions under this notice of opportunity for a hearing
must be filed in two copies. Except for data and information prohibited
from public disclosure under 21 U.S.C. 331(j) or 18 U.S.C. 1905, the
submissions may be seen at the Dockets Management Staff (see ADDRESSES)
between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to
the docket at https://www.regulations.gov.
This notice is issued under section 505(e) of the FD&C Act and
under authority delegated to the Director of CDER by the Commissioner
of Food and Drugs.
IV. References
The following references are on display at the Dockets Management
Staff (see ADDRESSES) and are available for viewing by interested
persons between 9 a.m. and 4 p.m., Monday through Friday; they are also
available electronically at https://www.regulations.gov. FDA has
verified the website address, as of the date this document publishes in
the Federal Register, but websites are subject to change over time.
1. Letter from Leslie Ball, FDA, to Roger Hayes, Cetero Research,
July 26, 2011.
2. FDA, ``Notification to Pharmaceutical Companies: Acceptance of
third-party data integrity audit for Cetero studies conducted from
March 1, 2008, to August 31, 2009'' (https://wayback.archive-it.org/7993/20170113203457/http:/www.fda.gov/Drugs/DrugSafety/ucm265559.htm), accessed September 10, 2019.
3. Letter from Keith Webber, FDA, to InvaGen Pharmaceuticals, Inc.,
August 9, 2011.
4. Letter from Carol A. Holquist, FDA, to InvaGen Pharmaceuticals,
Inc., August 19, 2016.
5. Letter from Ram Mohan Kathuroju, InvaGen Pharmaceuticals, Inc.,
to FDA, September 16, 2016.
6. Letter from Carol A. Holquist, FDA, to InvaGen Pharmaceuticals,
Inc., April 24, 2017.
Dated: October 21, 2019.
Janet Woodcock,
Director, Center for Drug Evaluation and Research.
[FR Doc. 2019-23461 Filed 10-25-19; 8:45 am]
BILLING CODE 4164-01-P
